Annovis Bio Inc (NYSEAMERICAN:ANVS) is leading the biggest gainer list in the pre-market session on Friday.
Investors are reacting positively to the company’s news about new results from a double-blind, placebo-controlled study of ANVS401, it’s lead drug candidate for the treatment of AD and PD.
The company said Patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11). The 11-part test is one of the most frequently used tests to measure impaired cognition in clinical trials for AD.
At the time of writing, ANVS stock is trading up over 40% to $37. The stock is one the biggest gainers this year with a jump of 350%. Moreover, the stock is about 20% away from its 52-week high of $47.99.